DE69123582T2 - Behandlung des chronischen nierenversagens mit imidazol-angiotensin-ii-rezeptorantagonisten - Google Patents

Behandlung des chronischen nierenversagens mit imidazol-angiotensin-ii-rezeptorantagonisten

Info

Publication number
DE69123582T2
DE69123582T2 DE69123582T DE69123582T DE69123582T2 DE 69123582 T2 DE69123582 T2 DE 69123582T2 DE 69123582 T DE69123582 T DE 69123582T DE 69123582 T DE69123582 T DE 69123582T DE 69123582 T2 DE69123582 T2 DE 69123582T2
Authority
DE
Germany
Prior art keywords
imidazole
angiotensin
treating chronic
receptor antagonists
chronic kidney
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69123582T
Other languages
English (en)
Other versions
DE69123582D1 (de
Inventor
David Carini
John Duncia
Pancras Wong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
EIDP Inc
Original Assignee
EI Du Pont de Nemours and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by EI Du Pont de Nemours and Co filed Critical EI Du Pont de Nemours and Co
Publication of DE69123582D1 publication Critical patent/DE69123582D1/de
Application granted granted Critical
Publication of DE69123582T2 publication Critical patent/DE69123582T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69123582T 1990-06-22 1991-06-07 Behandlung des chronischen nierenversagens mit imidazol-angiotensin-ii-rezeptorantagonisten Expired - Lifetime DE69123582T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54235190A 1990-06-22 1990-06-22
PCT/US1991/003906 WO1992000067A2 (en) 1990-06-22 1991-06-07 Treatment of chronic renal failure with imidazole angiotensin-ii receptor antagonists

Publications (2)

Publication Number Publication Date
DE69123582D1 DE69123582D1 (de) 1997-01-23
DE69123582T2 true DE69123582T2 (de) 1997-05-15

Family

ID=24163446

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69123582T Expired - Lifetime DE69123582T2 (de) 1990-06-22 1991-06-07 Behandlung des chronischen nierenversagens mit imidazol-angiotensin-ii-rezeptorantagonisten

Country Status (8)

Country Link
EP (1) EP0533840B1 (de)
JP (2) JPH05509086A (de)
AT (1) ATE146076T1 (de)
CA (1) CA2085584C (de)
DE (1) DE69123582T2 (de)
DK (1) DK0533840T3 (de)
GR (1) GR3022035T3 (de)
WO (1) WO1992000067A2 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2058198A1 (en) * 1991-01-04 1992-07-05 Adalbert Wagner Azole derivatives, process for their preparation, and their use
JP3810020B2 (ja) * 1993-04-22 2006-08-16 武田薬品工業株式会社 腎疾患の予防または治療剤
FR2719598B1 (fr) * 1994-05-03 1996-07-26 Rhone Poulenc Chimie Composition élastomère silicone et ses applications, notamment pour l'enduction de sac gonflable, destiné à la protection d'un occupant de véhicule.
AU677702B2 (en) * 1994-10-13 1997-05-01 Takeda Pharmaceutical Company Limited A prophylactic or therapeutic drug for renal diseases
US6498142B1 (en) * 1996-05-06 2002-12-24 Curis, Inc. Morphogen treatment for chronic renal failure
JP5033276B2 (ja) 1997-05-05 2012-09-26 ストライカー コーポレイション 急性腎不全の治療
SE9903028D0 (sv) 1999-08-27 1999-08-27 Astra Ab New use
EP1353662B1 (de) 2001-01-26 2007-04-18 Chugai Seiyaku Kabushiki Kaisha Verfahren zur behandlung von erkrankungen mit malonyl coa-decarboxylase-inhibitoren
CA2435067C (en) 2001-01-26 2011-11-15 Chugai Seiyaku Kabushiki Kaisha Malonyl-coa decarboxylase inhibitors useful as metabolic modulators
JP4267920B2 (ja) 2001-01-26 2009-05-27 中外製薬株式会社 代謝調節剤として有用なマロニル−ＣｏＡ脱炭酸酵素阻害剤
US7709510B2 (en) 2001-02-20 2010-05-04 Chugai Seiyaku Kabushiki Kaisha Azoles as malonyl-CoA decarboxylase inhibitors useful as metabolic modulators
HU229431B1 (en) 2001-02-20 2013-12-30 Chugai Pharmaceutical Co Ltd Azoles as malonyl-coa decarboxylase inhibitors useful as metabolic modulators
US7696365B2 (en) 2003-08-01 2010-04-13 Chugai Seiyaku Kabushiki Kaisha Heterocyclic compounds useful as malonyl-CoA decarboxylase inhibitors
WO2005037258A2 (en) 2003-08-01 2005-04-28 Chugai Seiyaku Kabushiki Kaisha Cyanoguanidine-based azole compounds useful as malonyl-coa decarboxylase inhibitors
CA2533763C (en) 2003-08-01 2012-11-20 Chugai Seiyaku Kabushiki Kaisha Cyanoamide compounds useful as malonyl-coa decarboxylase inhibitors
JP4648317B2 (ja) 2003-08-01 2011-03-09 中外製薬株式会社 マロニル−ＣｏＡデカルボキシラーゼ阻害剤として有用なピペリジン化合物
US8257797B2 (en) 2003-11-03 2012-09-04 Bluestar Silicones France Silicone composition and process that is useful for improving the tear strength and the combing strength of an inflatable bag for protecting an occupant of a vehicle
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EA020466B1 (ru) 2007-06-04 2014-11-28 Синерджи Фармасьютикалз Инк. Агонисты гуанилатциклазы, пригодные для лечения желудочно-кишечных нарушений, воспаления, рака и других заболеваний
WO2009134741A1 (en) * 2008-04-29 2009-11-05 Theravance, Inc. Dual-acting antihypertensive agents
CA2726917C (en) 2008-06-04 2018-06-26 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
CA2730603C (en) 2008-07-16 2019-09-24 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2011077712A1 (ja) * 2009-12-22 2011-06-30 興和株式会社 新規な１－（ビフェニル－４－イル－メチル）－１ｈ－イミダゾール誘導体及びこれを含有する医薬
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
EP2970384A1 (de) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonisten der guanylatcyclase und deren verwendungen
CN113388007A (zh) 2013-06-05 2021-09-14 博士医疗爱尔兰有限公司 鸟苷酸环化酶c的超纯激动剂、制备和使用所述激动剂的方法
BR112018077075A2 (pt) 2016-06-29 2019-04-30 Universite De Montreal heterociclos de biarilmetila

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5015651A (en) * 1988-01-07 1991-05-14 E. I. Du Pont De Nemours And Company Treatment of hypertension with 1,2,4-angiotensin II antagonists
EP0955294B1 (de) * 1989-06-14 2003-09-24 Smithkline Beecham Corporation Imidazoalkensäure
KR0163595B1 (ko) * 1989-06-30 1998-12-01 미리암디, 메코너헤이 치환된 이미다졸
CA2032289A1 (en) * 1989-12-29 1991-06-30 Joseph A. Finkelstein Substituted 5-(alkyl) carboxamide imidazoles

Also Published As

Publication number Publication date
ATE146076T1 (de) 1996-12-15
CA2085584A1 (en) 1991-12-23
DK0533840T3 (da) 1996-12-30
EP0533840A1 (de) 1993-03-31
DE69123582D1 (de) 1997-01-23
EP0533840B1 (de) 1996-12-11
WO1992000067A2 (en) 1992-01-09
CA2085584C (en) 2003-02-11
JPH05509086A (ja) 1993-12-16
JPH11228410A (ja) 1999-08-24
GR3022035T3 (en) 1997-03-31
WO1992000067A3 (en) 1993-05-27

Similar Documents

Publication Publication Date Title
DE69123582D1 (de) Behandlung des chronischen nierenversagens mit imidazol-angiotensin-ii-rezeptorantagonisten
EP0803252A3 (de) Behandlung der Schädigung des Zentralnervensystems mit Imidazolangiotensin-II-Rezeptor-Antagonisten
NO1995004I1 (no) Losartan/ 2-butyl-4-klor-1-((2'-(1H-tetrazol-5-yl)-bifenyl-4-yl)-metyl)-5-(hydroksylmetyl)-imidazol
ATE171447T1 (de) Benzimidazole derivate
ATE103604T1 (de) Substituierte 5-((tetrazolyl)alkenyl>-imidazole.
MX9204737A (es) Acidos imidazolil-alquenoicos
TR199801350T2 (xx) Yeni sikloalkil ikameli imidazoller.
ES2150567T3 (es) Antagonistas del factor de liberacion de la corticotropina.
DE69025473D1 (de) Substituierte imidazole und ihre verwendung als hemmmstoff fur angiotensin ii
TR200000014T2 (tr) Yeni ikameli imidazol bileşimleri.
DK0403159T3 (da) Imidazolylalkensyrer
ATE371645T1 (de) Naphthalinderivate, die sich an den ep4?rezeptor binden
BR9608591A (pt) Compostos de imidazol
RO118870B1 (ro) Monometansulfonat de acid (e)-alfa-[2-n-butil-1-[(4-carboxifenil)metil]-1h-imidazol-5-il]metilen-2-tiofenpropionic, procedee de preparare şi compoziţii farmaceutice
NO972324L (no) Orale blandinger inneholdende Ondansetron
DE60126652D1 (de) Indolderivate
DK0492105T3 (da) Angiotensin-II-receptor-blokkerer til behandling af cardial hypertrofi
RS51872B (en) DIMER UNITS FGF RECEPTOR AGONISTS
FI905481A0 (fi) Substituerade n-(imidazolyl) -alkylalaninderivat.
DK1019048T3 (da) Anvendelse af en angiotensin II-reseptorantagonist til fremstilling af lægemidler til forøgelse af overlevelsesfrekvensen af nyretransplanterede patienter
WO1992020651A3 (en) N-(heteroaryl)-imidazolyl-alkenoic acids
MY111445A (en) Ondansetron for rectal administration
BRPI0408979A (pt) uso de um antagonista e receptor de tipo 1 da angiotensina ii sozinho ou em combinação com uma substáncia anti-hipertensiva metabolicamente neutra, e, método para o tratamento e/ou prevenção de sìndrome metabólica

Legal Events

Date Code Title Description
8364 No opposition during term of opposition